Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503174 · ClinicalTrials.gov registry record
Control-IQ Observational (CLIO) Post-Approval Study
A clinical trial, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- 3,157
- Enrollment target
NCT04503174: Completed study, sponsored by Tandem Diabetes Care.
NCT04503174 is a clinical trial that has completed, run by Tandem Diabetes Care. The registered enrollment target is 3,157 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04503174 has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- 3,157 participants
- Enrollment target
Study Summary
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
Primary Outcome
Overall incidence rate of events per 100 patient years
Interventions
- DEVICE t:slim X2 pump with Control-IQ technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,157 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2023-06-26 |
What the finished NCT04503174 record still lists
NCT04503174 is an observational study that tracks outcomes without assigning an intervention. Its 3,157 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which t:slim X2 pump with Control-IQ technology is the first listed.
NCT04503174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04503174 about?
NCT04503174 is a clinical study titled "Control-IQ Observational (CLIO) Post-Approval Study". Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
What is the current status of trial NCT04503174?
This trial is currently completed. The enrollment target is 3,157 participants. The study started on 2020-08-04. Estimated completion is 2023-06-26.
What interventions are being tested in trial NCT04503174?
The interventions under investigation include: t:slim X2 pump with Control-IQ technology (DEVICE).
Who is sponsoring clinical trial NCT04503174?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06224205 · 3,150 participants · NA
Digital Detection of Dementia (D Cubed) Studies: D3
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI